New technology, services emerge to support disabled Latinos – Yahoo Tech

Quality of life for U.S. Latinos who have a disability tends to be worse than for other demographics, spurring efforts to develop new technologies that could help.
Why it matters: One in six Latino adults in the U.S. has a disability. As the Hispanic population grows, more people could be in need of support.
Stay on top of the latest market trends and economic insights with Axios Markets. Subscribe for free
What’s happening: More than 5.4 million Hispanics — about 9%, of all ages —have some form of disability in the U.S., according to an analysis of census data by the University of New Hampshire's Institute on Disability.
That's a lower rate overall compared to their white, Black and Native American peers, but Hispanics report greater levels of unemployment due to disability, higher school dropout rates and lower use of assistive devices.
Latinos have twice the risk of non-Hispanic whites when it comes to developing worse health outcomes and limits to performing usual activities.
Language barriers, fears over immigration status, cultural stigmas against seeking help, and not having health insurance can hinder the advancement of Latinos who have disabilities ranging from mental health disorders and physical differences to cognitive impairments.
Some technologies and services are emerging to support Latinos with disabilities. They include:
A Mexican teen is developing an app to help sign language speakers and people who aren’t deaf communicate easier by translating, with video assistance, sign language to text and voice, and vice versa.
A video relay service from Purple Communications provides sign language interpretation in both Spanish and English and has just joined forces with Meta for easier use in Facebook products and video chatting.
The nonprofit World Institute on Disability has a range of digital tools, including Proyecto Visión, a bilingual work training platform that also offers information on how to find health insurance through a job, budgeting or disability benefits.
By the numbers: Of Hispanics with a disability in the U.S., 26% live in poverty compared to 32% of Black people with a disability and 17% of white non-Hispanic Americans who are disabled, according to the University of New Hampshire analysis.
Latinos with disabilities are less likely to be insured: about 89% have coverage nationwide in comparison to 94% on average for Black, white non-Hispanic, Asian and Native American people with a disability.
What they’re saying: “Technology has certainly improved our arena for communication, to feel more connected, [through] apps that pick up speech and translate it, so we can enjoy activities like guided tours at a museum,” Elvia Guillermo Aguilar, who is in charge of intercultural alliances at the Equity, Diversity and Inclusion office of Gallaudet University, told Axios Latino.
The big picture: About 13% of the population in Latin America and the Caribbean — regions with even greater accessibility challenges — has a disability.
In cities like La Paz, Bolivia, NGOs and municipal governments have made progress improving transportation access for people with disabilities. They've also created playgrounds and parks designed for kids in wheelchairs in Brazil.
A university with dedicated workshops and areas for rehabilitation services is being built in Cali, Colombia, by the nonprofit Asodisvalle.
More from Axios: Sign up to get the latest market trends with Axios Markets. Subscribe for free
When it comes to Covid-19 vaccines, Pfizer (PFE) and Moderna (MRNA) get all the headlines. To an extent, that makes sense. After all, both Pfizer's Comirnaty Covid vaccine and Moderna's Spikevax use mRNA technology to elicit an immune response without ever actually introducing a virus of any sort into the body. In the Western world, these two are the most popular and widespread vaccines available for immunizing patients against the novel coronavirus SARS-CoV-2. Still, as the pandemic enters its
Novavax stock and shares of other vaccine makers fell Friday after the Supreme Court blocked the Biden administration’s vaccine mandate for companies that employ 100 workers or more. The Supreme Court’s conservative majority dealt a major setback to the Biden administration’s effort to boost vaccination rates on Thursday, ruling that the government didn’t have the unilateral power to impose the mandate for all large businesses through the Occupational Safety and Health Administration. “These SCOTUS decisions are in alignment with what we expected,” wrote Raymond James analyst Chris Meekins in a research note.
CRISPR stocks will face make-or-break moments in 2022 as Big Pharma joins their quest to cure serious diseases with gene editing technology.
Donna Steele started in the shipping department of Tigra USA, a saw-blade company, rising to become chief executive.
Some travel and service employers say they will keep Covid vaccine and testing mandates. Others express relief at the court's opinion.
By John Vandermosten, CFA NASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT Since Our Last Update Since our last update, Heat Biologics, Inc. (NASDAQ:HTBX) has announced several major developments including the unveiling of Heat’s RapidVax novel cellular vaccine platform, a planned acquisition of Elusys Therapeutics, and new PTX-35 preclinical data in organ transplantation. Heat also looks forward
Controversial podcast host concedes debate after broadcaster points out the flaw in his case against the Pfizer vaccine
Rockwell Medical Inc's (NASDAQ: RMTI) partner, Jeil Pharmaceutical Co Ltd, has received regulatory approval in South Korea for Triferic Injection for iron supplementation therapy and maintaining hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease. Rockwell Medical has an exclusive license agreement with Jeil to commercialize Triferic in South Korea. Regarding the license, Rockwell Medical has received an upfront fee and will be eligible for milestone payments and roya
The FDA placed a hold on the company's planned clinical trial of an experimental Alzheimer's disease drug.
U.S. Labor Secretary Marty Walsh pointed to survey results that show an overwhelming majority of young people hold a favorable view of unions.
Is Pfizer stock a buy after inking a deal with Beam Therapeutics for its CRISPR technology, base editing? Is PFE stock a buy now?
A Cook County judge this week was caught on a YouTube livestream mocking an attorney who had appeared before him for arguments earlier in the day. “Can you imagine waking up next to her every day? Oh, my God,” Judge William Raines said of attorney Jennifer Bonjean. “… I couldn’t have a visual on that if you paid me.” A link to the video of Tuesday’s livestreamed court call was available for …
Walmart’s (WMT) female truck drivers must either go to work wearing company-provided men’s pants, or pay to buy and launder their own uniform-compliant garments, according to a new lawsuit filed in federal court in Alabama.
The Food and Drug Administration placed Denali's Alzheimer's test on hold Thursday, sending DNLI stock into a dive.
A rival to the company's leading pipeline drug wins conditional marketing authorization in a big market abroad.
A video of a Spartanburg teenager and daughter of a WSPA news anchor has gone viral after her racist rant surfaced on social media. Amy Wood has responded to the video.
The company's blockbuster cancer drug Keytruda was approved in Japan to treat patients with certain types of endometrial cancer.
Dividends can be a great source of passive income, and they can also help supercharge your portfolio's growth if you take advantage of automatic dividend reinvestment. In other words, no matter your investment style, dividend-paying stocks can help you reach your goals — and one that looks like a particularly excellent option right now is Amgen (NASDAQ: AMGN). For instance, sales of Neulasta, which stimulates the production of infection-fighting white blood cells in cancer patients, decreased by 25% year over year in the third quarter to $415 million.
U of L kidney doctor Tweet shooting down urine COVID cure goes viral
Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) were skyrocketing 40.2% higher this week as of the market close on Thursday, according to on data from S&P Global Market Intelligence. BioCryst announced preliminary net revenue for hereditary angioedema (HAE) drug Orladeyo of $45.6 million for the fourth quarter of 2021. In addition, BioCryst stated that it has begun enrolling patients in two pivotal clinical studies evaluating its experimental oral Factor D inhibitor, BCX990, in treating rare genetic disease paroxysmal nocturnal hemoglobinuria (PNH).


Leave a Comment